| Daniel Hensgen, AG-ACNP | |
|
1836 South Ave, La Crosse, WI 54601-5429 | |
| (608) 782-7300 | |
| Not Available |
| Full Name | Daniel Hensgen |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 1836 South Ave, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053729491 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | 5850-33 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Gundersen Lutheran Medical Center | La crosse, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gundersen Lutheran Medical Center Inc | 2163331414 | 800 |
News Archive
Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.
ARIAD Pharmaceuticals, Inc. today announced updated clinical data from a fully enrolled and ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
Challenging a half-century-old theory about why chemotherapy agents target cancer, scientists at Dana-Farber Cancer Institute have devised a test that can predict how effective the drugs will be by determining whether a patient's tumor cells are already "primed" for death.
In addition to its effect on chronic tics, cognitive behavioural therapy (CBT) can change the brain function of people with Tourette syndrome.
› Verified 8 days ago
| Entity Name | Gundersen Lutheran Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376593442 PECOS PAC ID: 2163331414 Enrollment ID: O20130619000254 |
News Archive
Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.
ARIAD Pharmaceuticals, Inc. today announced updated clinical data from a fully enrolled and ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
Challenging a half-century-old theory about why chemotherapy agents target cancer, scientists at Dana-Farber Cancer Institute have devised a test that can predict how effective the drugs will be by determining whether a patient's tumor cells are already "primed" for death.
In addition to its effect on chronic tics, cognitive behavioural therapy (CBT) can change the brain function of people with Tourette syndrome.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Hensgen, AG-ACNP 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Daniel Hensgen, AG-ACNP 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 |
News Archive
Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.
ARIAD Pharmaceuticals, Inc. today announced updated clinical data from a fully enrolled and ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
Challenging a half-century-old theory about why chemotherapy agents target cancer, scientists at Dana-Farber Cancer Institute have devised a test that can predict how effective the drugs will be by determining whether a patient's tumor cells are already "primed" for death.
In addition to its effect on chronic tics, cognitive behavioural therapy (CBT) can change the brain function of people with Tourette syndrome.
› Verified 8 days ago
Stacie Strong, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2500 State Rd # 33, La Crosse, WI 54601 Phone: 608-775-5858 | |
Julie Sonsalla, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Naomi Muthoni Ruiru, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Catherine A Ziegler, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 800 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 | |
Lisa Malmo, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 | |
Tneshia Janeen Sweat, NNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Kathleen Marie Grangaard, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 |